Related Experiment Video

Updated: Mar 26, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.3K

VIP and PACAP analogs regulate therapeutic targets in high-risk neuroblastoma cells

Madryssa de Boisvilliers1, Florian Perrin1, Salima Hebache1

  • 1Université de Poitiers, Équipe Récepteurs, Régulations et Cellules Tumorales (2RCT), Pôle Biologie Santé, Bât. B36/B37, UFR Sciences Fondamentales et Appliquées, 1 rue Georges Bonnet TSA, 51106 86073 Poitiers Cedex 9, France.

Peptides
|January 31, 2016
PubMed

Insights

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) analogs show potential in treating high-risk neuroblastoma (NB). These neuropeptides may reduce cancer aggressiveness by inhibiting MYCN and ALK signaling and decreasing cell invasion.

Area of Science:

  • Oncology
  • Neuroscience
  • Molecular Biology

Background:

  • Neuroblastoma (NB) is a pediatric cancer with high-risk subtypes requiring novel therapies.
  • Current treatments for high-risk NB focus on inducing cell differentiation and inhibiting MYCN and ALK signaling pathways.
  • Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are neuropeptides linked to NB differentiation.

Purpose of the Study:

  • To investigate the therapeutic potential of VIP and PACAP analogs in high-risk neuroblastoma.
  • To examine the effects of these neuropeptides on MYCN expression, ALK signaling, and cell invasion in NB cell lines.

Main Methods:

  • Studied VIP and PACAP analogs in MYCN-amplified NB cell lines (SK-N-DZ, IMR-32) and ALK-mutated Kelly cells.
  • Assessed effects on neuritogenesis, MYCN expression, AKT activity, and cell invasion.
  • Analyzed expression of VIP/PACAP receptors (VPAC1, VPAC2, PAC1).

Main Results:

  • VIP induced neuritogenesis and reduced MYCN expression and invasion in specific NB cell lines.
  • VIP decreased AKT activity in ALK-mutated cells, with PKA-dependent effects.
  • [Hyp(2)]PACAP-27 demonstrated higher efficacy than VIP in Kelly cells.
  • All tested NB cell lines expressed VPAC1, VPAC2, and PAC1 receptor genes.

Conclusions:

  • VIP and PACAP analogs exhibit potential for reducing the aggressiveness of high-risk neuroblastoma.
  • These neuropeptides modulate key molecular targets and cellular processes relevant to NB therapy.
  • Further research into VIP and PACAP analogs could lead to new therapeutic strategies for pediatric cancer.
Keywords:
AKTALKDifferentiationInvasionMYCNPKA

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
740
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K